Brighton, MA, United States of America

Arvind Hundal

USPTO Granted Patents = 6 

Average Co-Inventor Count = 11.0

ph-index = 5

Forward Citations = 331(Granted Patents)


Company Filing History:


Years Active: 1998-2010

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Arvind Hundal: Innovator in Amyloid Research

Introduction

Arvind Hundal is a prominent inventor based in Brighton, MA, with a noteworthy portfolio of six patents primarily focused on the modulation of amyloid aggregation. His innovative contributions target significant advances in understanding and treating amyloidogenic diseases, paving the way for potential therapeutic developments.

Latest Patents

One of his latest patents involves compounds that modulate the aggregation of amyloidogenic proteins and peptides. The disclosed modulators can either promote amyloid aggregation or, preferably, inhibit the natural process. In one embodiment, these compounds specifically impact the aggregation of natural β-amyloid peptides (β-AP). These modulators consist of an Aβ aggregation core domain connected to a modifying group, which collectively alters aggregation or hinders the neurotoxicity of the natural β-amyloid peptides upon contact. Moreover, these potent modulators can modify the aggregation of natural β-APs even when in a molar excess relative to the compounds. The patent also covers pharmaceutical compositions utilizing these compounds, along with methods for diagnosing and treating amyloidogenic diseases.

Career Highlights

Arvind Hundal has significantly contributed to the field of amyloid research through his work at Praecis Pharmaceuticals, Inc. His commitment to innovation in pharmaceuticals has positioned him as a leading figure in the development of treatments for complex diseases related to amyloid aggregation.

Collaborations

Throughout his career, Hundal has collaborated with notable professionals in the field, including Mark A. Findeis and Howard Benjamin. These collaborations have enhanced his research endeavors, fostering an environment of shared knowledge and expertise that drives forward innovation in amyloid research.

Conclusion

Arvind Hundal's inventive work in the modulation of amyloid aggregation represents a critical step in combating amyloidogenic diseases. His patents reflect a commitment to scientific advancement and an understanding of the complexities associated with amyloid proteins, positioning him as a significant contributor to the future of biomedical innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…